Successful Treatment of Conjunctival Lymphangiectasia With Subconjunctival Injection of Bevacizumab

被引：16

作者：

Tan, Jeremy C. K. ^{[1
]}

Mann, Stephen ^{[2
]}

Coroneo, Minas T. ^{[1
,3
]}

机构：

[1] Prince Wales Hosp, Dept Ophthalmol, Sydney, NSW, Australia

[2] Hispath, Specialist Pathologists, Sydney, NSW, Australia

[3] Ophthalm Surg, Sydney, NSW, Australia

来源：

CORNEA | 2016年 / 35卷 / 10期

关键词：

conjunctival lymphangiectasia; VEGF; bevacizumab; ENDOTHELIAL GROWTH-FACTOR; FACTOR C; LYMPHANGIOGENESIS; ANGIOGENESIS; DISEASES; CORNEAL; SYSTEM;

D O I：

10.1097/ICO.0000000000000899

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose:To report a novel intervention for the treatment of conjunctival lymphangiectasiasubconjunctival injection of bevacizumab.Methods:A 53-year-old white male presented with a 3-month history of right ocular discomfort and redness unresponsive to conventional topical treatment of lubricants and steroids. A clinical diagnosis of conjunctival lymphangiectasia was confirmed by biopsy. Bevacizumab (25 mg/mL) was injected subconjunctivally into the affected area.Results:An improvement in the degree of conjunctival chemosis was evident at 5 days postinjection. At 1-month follow-up, symptoms had fully resolved. No recurrence had been observed at 3 years' follow-up.Conclusions:Subconjunctival bevacizumab injection may be an effective treatment for conjunctival lymphangiectasia.

引用

页码：1375 / 1377

页数：3

共 16 条

[1] Successful Treatment of Diffuse Pulmonary Lymphangiomatosis With Bevacizumab [J].

Aman, Jurjan ;

Thunnissen, Erik ;

Paul, Marinus A. ;

Amerongen, Geerten P. van Nieuw ;

Vonk-Noordegraaf, Anton .

ANNALS OF INTERNAL MEDICINE, 2012, 156 (11) :839-840

[2] Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis [J].

Bock, Felix ;

Onderka, Jasmine ;

Dietrich, Tina ;

Bachmann, Bjorn ;

Kruse, Friedrich E. ;

Paschke, Matthias ;

Zahn, Grit ;

Cursiefen, Claus .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2007, 48 (06) :2545-2552

[3] Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases [J].

Bock, Felix ;

Maruyama, Kazuichi ;

Regenfuss, Birgit ;

Hos, Deniz ;

Steven, Philipp ;

Heindl, Ludwig M. ;

Cursiefen, Claus .

PROGRESS IN RETINAL AND EYE RESEARCH, 2013, 34 :89-124

[4]

Cueni Leah N., 2008, Lymphatic Research and Biology, V6, P109, DOI 10.1089/lrb.2008.1008

[5] Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin) [J].

Cursiefen, C ;

Schlötzer-Schrehardt, U ;

Breiteneder-Geleff, S ;

Holbach, LM .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2001, 239 (08) :628-632

[6] VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment [J].

Cursiefen, C ;

Chen, L ;

Borges, LP ;

Jackson, D ;

Cao, JT ;

Radziejewski, C ;

D'Amore, PA ;

Dana, MR ;

Wiegand, SJ ;

Streilein, JW .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :1040-1050

[7]

Fraunfelder FW, 2009, ARCH OPHTHALMOL-CHIC, V127, P1686, DOI 10.1001/archophthalmol.2009.306

[8] Blockade of Prolymphangiogenic Vascular Endothelial Growth Factor C in Dry Eye Disease [J].

Goyal, Sunali ;

Chauhan, Sunil K. ;

Dana, Reza .

ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (01) :84-89

[9] Removal of Lymphangiectasis Using High-Frequency Radio Wave Electrosurgery [J].

Han, Kyung E. ;

Choi, Chul Y. ;

Seo, Kyoung Y. .

CORNEA, 2013, 32 (04) :547-549

[10] Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function [J].

Kajiya, Kentaro ;

Hirakawa, Satoshi ;

Detmar, Michael .

AMERICAN JOURNAL OF PATHOLOGY, 2006, 169 (04) :1496-1503

← 1 2 →